210 related articles for article (PubMed ID: 26530362)
21. [Pro-prostate-specific antigen and its related indexes in the diagnosis of prostate cancer].
Jiang L; Lu YP
Zhonghua Nan Ke Xue; 2015 Jul; 21(7):655-8. PubMed ID: 26333230
[TBL] [Abstract][Full Text] [Related]
22. PSA and new biomarkers within multivariate models to improve early detection of prostate cancer.
Stephan C; Cammann H; Meyer HA; Lein M; Jung K
Cancer Lett; 2007 Apr; 249(1):18-29. PubMed ID: 17292541
[TBL] [Abstract][Full Text] [Related]
23. Current biomarkers for diagnosing of prostate cancer.
Stephan C; Jung K; Ralla B
Future Oncol; 2015; 11(20):2743-55. PubMed ID: 26358139
[TBL] [Abstract][Full Text] [Related]
24. Biomarkers for prostate cancer.
Makarov DV; Loeb S; Getzenberg RH; Partin AW
Annu Rev Med; 2009; 60():139-51. PubMed ID: 18947298
[TBL] [Abstract][Full Text] [Related]
25. [The usefulness of percentage of free prostate specific antigen/prostate specific antigen density in the diagnosis of prostate cancer].
Han G; Gao JP; Cao XL; Hong BF; Tang J
Zhonghua Wai Ke Za Zhi; 2006 Mar; 44(6):379-81. PubMed ID: 16638346
[TBL] [Abstract][Full Text] [Related]
26. From pro-prostate specific antigen, [-2]pro-prostate specific antigen to Beckman Coulter phi: the evolution of new biomarkers for early detection of prostatic carcinoma.
Zhang MZ; Lu YP
Chin Med J (Engl); 2012 May; 125(9):1643-9. PubMed ID: 22800836
[TBL] [Abstract][Full Text] [Related]
27. [Evaluation of (-2)proPSA in combination with total PSA and free PSA for the early detection of prostate cancer].
Lamy PJ; Montels F; Tosi D; Leizour B; Bascoul-Mollevi C; Castan F; Roques S; Nielloud F; Rebillard X
Ann Biol Clin (Paris); 2013; 71(5):537-44. PubMed ID: 24113439
[TBL] [Abstract][Full Text] [Related]
28. On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.
Bangma CH; van Schaik RH; Blijenberg BG; Roobol MJ; Lilja H; Stenman UH
Eur J Cancer; 2010 Nov; 46(17):3109-19. PubMed ID: 21047594
[TBL] [Abstract][Full Text] [Related]
29. Prostate-specific antigen and other serum and urine markers in prostate cancer.
Stephan C; Ralla B; Jung K
Biochim Biophys Acta; 2014 Aug; 1846(1):99-112. PubMed ID: 24727384
[TBL] [Abstract][Full Text] [Related]
30. Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy.
Scattoni V; Lazzeri M; Lughezzani G; De Luca S; Passera R; Bollito E; Randone D; Abdollah F; Capitanio U; Larcher A; Lista G; Gadda GM; Bini V; Montorsi F; Guazzoni G
J Urol; 2013 Aug; 190(2):496-501. PubMed ID: 23466239
[TBL] [Abstract][Full Text] [Related]
31. Urinary Prostate Cancer Antigen 3 as a Tumour Marker: Biochemical and Clinical Aspects.
Schmid M; Hansen J; Chun FK
Adv Exp Med Biol; 2015; 867():277-89. PubMed ID: 26530372
[TBL] [Abstract][Full Text] [Related]
32. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
33. Complexed prostate specific antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 2.5 and 20 ng/ml: results of a prospective multicenter study.
Sözen S; Eskicorapci S; Küpeli B; Irkilata L; Altinel M; Ozer G; Uygur C; Alkibay T; Ozen H
Eur Urol; 2005 Mar; 47(3):302-7. PubMed ID: 15716190
[TBL] [Abstract][Full Text] [Related]
34. Electrophoretic subforms of free prostate-specific antigen in serum as promising diagnostic tool in prostate cancer diagnostics.
Jung K; Hoesel W; Reiche J; Deger S; Kramer J; Loening SA; Lein M; Stephan C
Urology; 2007 Feb; 69(2):320-5. PubMed ID: 17320672
[TBL] [Abstract][Full Text] [Related]
35. Usefulness of proprostate-specific antigen in the diagnosis of prostate cancer.
Filella X; Alcover J; Molina R; Luque P; Corral JM; Augé JM; Coca F
Anticancer Res; 2007; 27(1B):607-10. PubMed ID: 17348449
[TBL] [Abstract][Full Text] [Related]
36. [Tumor markers in prostate cancer--clinical significance and future prospect of prostate specific antigen (PSA)].
Tsuchiya N; Ohyama C; Habuchi T
Gan To Kagaku Ryoho; 2005 Feb; 32(2):275-80. PubMed ID: 15751649
[TBL] [Abstract][Full Text] [Related]
37. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection.
Jansen FH; van Schaik RH; Kurstjens J; Horninger W; Klocker H; Bektic J; Wildhagen MF; Roobol MJ; Bangma CH; Bartsch G
Eur Urol; 2010 Jun; 57(6):921-7. PubMed ID: 20189711
[TBL] [Abstract][Full Text] [Related]
38. The potential role of prebiopsy magnetic resonance imaging combined with prostate-specific antigen density in the detection of prostate cancer.
Kubota Y; Kamei S; Nakano M; Ehara H; Deguchi T; Tanaka O
Int J Urol; 2008 Apr; 15(4):322-6; discussion 327. PubMed ID: 18380820
[TBL] [Abstract][Full Text] [Related]
39. [[-2] proPSA: A Novel Marker of Prostate Cancer].
Ishikura K
Rinsho Byori; 2015 Jan; 63(1):84-93. PubMed ID: 26524883
[TBL] [Abstract][Full Text] [Related]
40. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy.
Perdonà S; Bruzzese D; Ferro M; Autorino R; Marino A; Mazzarella C; Perruolo G; Longo M; Spinelli R; Di Lorenzo G; Oliva A; De Sio M; Damiano R; Altieri V; Terracciano D
Prostate; 2013 Feb; 73(3):227-35. PubMed ID: 22821756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]